Author:
Tsunoda Shinichi,Kamada Haruhiko,Yamamoto Yoko,Ishikawa Tomoyoshi,Matsui Junji,Koizumi Keiichi,Kaneda Yoshihisa,Tsutsumi Yasuo,Ohsugi Yoshiyuki,Hirano Takashi,Mayumi Tadanori
Reference32 articles.
1. The fate of interleukin-2 after in vivo administration;Donohue;J. Immunol.,1983
2. Influence of renal and hepatic failure on the pharmacokinetics of recombinant human granulocyte colony-stimulating factor (KRN8601) in the rat;Tanaka;Cancer Res.,1990
3. A progress report on the treatment of 157 patients with advanced cancer using lymphokine activated killer cells and interleukin 2 alone;Rosenberg;New Engl. J. Med.,1987
4. Phase I study of recombinant human tumor necrosis factor;Kimura;Cancer Chemother. Pharmacol.,1987
5. Molecular design of hybrid tumor necrosis factor-α III: polyethylene glycol-modified tumor necrosis factor-α has markedly enhanced antitumor potency due to longer plasma half-life and higher tumor accumulation;Tsutsumi;J. Pharmacol. Exp. Ther.,1996